Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030

Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.

Musetti S, Leaf H. Tinagl1 gene therapy for tumor-wide remodeling of triple negative breast cancer. Poster presented at the 2020 32nd EORTC-NCI-AACR Symposium; October 26, 2020. [abstract] Eur J Cancer. 2020 Oct 1; 138(2):S37-8. doi: 10.1016/S0959-8049(20)31172-2

Parikh RC, Lorenzo M, Hess LM, Candrilli SD, Nicol S, Kaye JA. Treatment patterns and survival among older adults in the United States with advanced soft-tissue sarcomas. Clin Sarcoma Res. 2018 May 3;8:8. doi: 10.1186/s13569-018-0094-x

Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X, Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008

Maurel J, Lopez-Pousa A, Calabuig S, Bague S, Del Muro XG, Sanjuan X, Rubio-Casadevall J, Cuatrecasas M, Martinez-Trufero J, Horndler C, Fra J, Valverde C, Redondo A, Poveda A, Sevilla I, Lainez N, Rubini M, Garcia-Albeniz X, Martin-Broto J, de Alava E. Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. Clin Sarcoma Res. 2016 Jun 29;6:10. doi: 10.1186/s13569-016-0050-6

Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernan MA. Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May;51(7):817-24. doi: 10.1016/j.ejca.2015.03.003

Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Nov;50(16):2791-801. doi: 10.1016/j.ejca.2014.08.016

Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019

Sherrill B, Akhras K, Kaye J, Sandin R, Cappelleri J, Heyes A, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Poster presented at the European Multidisciplinary Cancer Congress of the European Cancer Organization; September 24, 2011. Stockholm, Sweden. [abstract] Eur J Cancer. 2011 Sep 1; 47(Suppl. 1):S261.

Horndler C, Gallego R, Garcia-Albeniz X, Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernandez-Martos C, Calatrava A, Marín-Aguilera M, Munoz J, Castellví-Bel S, Castells A, Rubini M, Gascon P, Maurel J. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study. Cancer Biol Ther. 2011 Jan 15;11(2):177-83.

Sharp L, Carsin AE, Cronin-Fenton DP, O'Driscoll D, Comber H. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. Eur J Cancer. 2009 May;45(8):1450-9. doi: 10.1016/j.ejca.2009.01.033

Guh S, Chen XB, Poulos C, Qi Z, Cao JW, von Seidlein L, Chen JC, Wang XY, Xing ZC, Nyamete A, Clemens J, Whittington D. Comparison of cost-of-illness with willingness-to-pay estimates to avoid shigellosis: evidence from China. Health Policy Plan. 2008 Mar 1;23(2):125-36.

Cronin-Fenton DP, Sharp L, Carsin AE, Comber H. Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study. Eur J Cancer. 2007 Feb;43(3):565-75. doi: 10.1016/j.ejca.2006.10.011

Canh DG, Whittington D, Thoa LTK, Utomo N, Hoa NT, Poulos C, Thuy DTD, Kim D, Nyamete A, Acosta C. Household demand for typhoid fever vaccines in Hue, Vietnam. Health Policy Plan. 2006 May 1;21(3):241-55.

Fortuny J, Benavente Y, Bosch R, García-Villanueva M, de Sevilla AF, de Sanjose S. Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer. 2005 Aug;41(12):1782-7. doi: 10.1016/j.ejca.2005.04.032